fda warning letters compounded semaglutide september 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of NCL Issues a Second Alert

Second Natures published outcomes data shows members on our GLP-1 programmes lose an average of 19.1% of their starting body weight at 12 months, with 77.7% achieving a clinically meaningful loss of 10% or more

This can slow metabolic rate and make long-term weight maintenance more difficult

Dietary considerations Semaglutide reduces appetite

Billing and Cancellation: Where the Real Friction Lives Noom settled a $62M class-action lawsuit in 2022 for sneaky subscription practices. The BBB publishes only 1 out of every 5 Noom complaints because volume is too high

Only functional nutrition and lifestyle correction

He wasnt involved with the new research